Últimas noticias sobre Bilibili (NASDAQ:BILI) Bolsa

BILIBILI INC-SPONSORED ADR

Bilibili

Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.

Government

News

Regulations

Emerging Markets

Movers

Tech

Media

BABA

BIDU

BILI

Citigourp Global Markets 2% Protected Notes Linked To The Djia

China podría mantener sin cambios sus tasas de interés mientras las acciones tecnológicas, incluidas Alibaba (BABA), Baidu y otras, bajan.

¿Qué está pasando con Alibaba (BABA) y otras acciones chinas el martes?

Bilibili Inc. - American Depositary Shares

Bilibili Inc

Bilia AB

WIIM

INLX

Intellinetics shares are trading higher. The company reported Q1 financial results.

MCHX

Marchex shares are trading higher after the company reported Q1 financial results and issued Q2 sales guidance above estimates.

NXPL

NextPlat shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

INBX

Inhibrx Biosciences shares are trading higher after the company reported better-than-expected Q1 EPS results.

Kevin O'Leary, entrepreneur and "Shark Tank" investor, is asking a question many American small business owners are starting to echo: "Why is that okay?"&nbsp;
His remarks come amid growing concern that U.S. businesses are being squeezed by two forces—intellectual property disputes with overseas factories and steep import tariffs that threaten to sink startups before they can grow.
O'Leary shared his frustrations during an April appearance on "<a href="https://youtu.be/9QtLeVpm53s">The Megyn Kelly Show</a>," where he reflected on the experience of Beth Benike, founder of Busy Baby. Her story, he said, represents a growing number of entrepreneurs caught in the crosshairs of trade and legal systems they can't control.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
<h2 class="wp-block-heading">Tariffs, Copycats And Courtrooms</h2>
Benike, a U.S. Army veteran, designs silicone placemats to help parents keep their babies' items off the floor. Her product gained popularity after a "<a href="https://www.youtube.com/watch?v=20jDl-c14jo">Shark Tank</a>" appearance. However, the decision to manufacture her products in China became problematic when tariffs increased dramatically.​
In an <a href="https://youtu.be/WjGzlSv0p4w">interview </a>with NewsNation on April13, Benike said that she budgeted for tariffs in the 20%-30% range. But after the Trump administration increased duties on Chinese imports, her costs jumped by 145%, stranding her shipment overseas.&nbsp;
She launched a <a href="https://www.gofundme.com/f/save-busy-baby-veteranowned-business-fighting-tariffs">GoFundMe campaign</a> in April to raise $229,000 just to get her products released.
O'Leary confirmed to Kelly he was familiar with the deal and Benike's dilemma. "This is certain death for some businesses," he said. "It's insane."
Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
But that wasn't the only issue on his radar.&nbsp;
O'Leary also criticized the growing number of cases where Chinese companies allegedly copy American inventions—and then sue the original creators in U.S. courts. "The crazy thing is Chinese companies use the American legal system to sue American companies after they've knocked them off," he said.
Benike took to<a href="https://www.linkedin.com/posts/bethfynbo_i-disagree-with-one-of-my-favorite-sharks-activity-7316871061222895617-Kxqu"> LinkedIn</a> on April 10 to argue that products with American patents should be exempt from the tariffs.&nbsp;
"Tariffs and IP theft should be two different conversations," she wrote. O'Leary, meanwhile, supports tariffs as a way to hold China accountable for what he described as widespread disregard for intellectual property rights.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a>
According to the<a href="https://homeland.house.gov/2025/02/12/threat-snapshot-ccp-espionage-repression-on-us-soil-is-growing/"> FBI</a>, approximately 80% of U.S. economic espionage cases in recent years have involved conduct benefiting China. The U.S. Trade Representative's<a href="https://www.chinaiplawupdate.com/2025/04/united-states-trade-representative-2025-national-trade-estimate-report-on-foreign-trade-barriers-china-needs-to-increase-damages-and-criminal-penalties-for-ip-infringement/"> 2025 National Trade</a> <a href="https://ustr.gov/about/policy-offices/press-office/press-releases/2025/march/ustr-releases-2025-national-trade-estimate-report">Estimate Report</a> also urged China to expand civil liability for misappropriation and increase criminal penalties for IP violations.
Meanwhile, small businesses remain caught in the middle. The American Action Forum<a href="https://www.americanactionforum.org/daily-dish/tariffs-and-small-businesses/"> estimated</a> that nearly 40% of Chinese imports are purchased by small businesses, many of which don't have the capital to weather a 100%+ tariff spike.
A<a href="https://budgetlab.yale.edu/research/where-we-stand-fiscal-economic-and-distributional-effects-all-us-tariffs-enacted-2025-through-april"> Budget Lab study from Yale</a> in March found that tariffs have driven up consumer prices by 2.3%, equaling a $3,800 hit to the average U.S. household. For small firms, that's the difference between growth and closure.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Why Is That Okay?' – Kevin O'Leary Blasts U.S. Legal System As Chinese Companies Sue Americans After Stealing Ideas

CDXS

Codexis shares are trading lower after the company reported worse-than-expected Q1 financial results.

American Shared Hospital Services shares are trading lower after the company reported Q1 financial results.

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Outperform and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

ADCT

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target

KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has outperformed the market over the past 10 years by 7.79% on an annualized basis producing an average annual return of 18.48%. Currently, KKR has a market capitalization of $111.67 billion. 
Buying $100 In KKR: If an investor had bought $100 of KKR stock 10 years ago, it would be worth $542.32 today based on a price of $125.39 for KKR at the time of writing.
<h3>KKR's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747323922_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In KKR 10 Years Ago Would Be Worth Today

Rosenblatt analyst Kevin Cassidy maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $4 price target.

INVZ

Rosenblatt Maintains Buy on Innoviz Technologies, Maintains $4 Price Target

<ul>
<li>Co-development of precision RNA therapeutics for inherited hearing loss treatment</li>
</ul>
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company&nbsp;to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed.&nbsp;

Contracts

Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-editing Therapeutics; If Lilly Exercises All Available Options Under The Agreement, The Total Deal Value Could Reach More Than $1.3B, As Well As Separate Royalties On Product Sales; The Upfront Payment Was Not Disclosed

Rosenblatt analyst Kevin Cassidy maintains Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral and maintains $3 price target.

BZAI

Rosenblatt Maintains Neutral on Blaize Holdings, Maintains $3 Price Target

Workhorse Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares are trading lower on Thursday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45432194/workhorse-group-reports-first-quarter-2025-results" rel="noreferrer noopener">reported first-quarter results</a>.
Workhorse registered quarterly earnings per share of $4.68 loss, missing the street view of a $3.44 loss. Quarterly sales of $640,920 missed the analyst consensus estimate of $2.35 million.
Quarterly sales decreased from $1.34 million&nbsp;primarily due to the Aero divestiture and decreased W4 CC and W56 truck sales.
During the three months ended March 31, Workhorse said that an institutional investor converted $5.9&nbsp;million of principal into common stock, and the company recorded a $3.3 million fair value net loss in interest expense.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/05/45430250/tesla-rival-baidu-expands-apollo-go-robotaxi-to-europe-sets-sights-on-turkey-amid-rising-competition-report" rel="noreferrer noopener">Tesla Rival Baidu Expands Apollo Go Robotaxi To Europe, Sets Sights On Turkey Amid Rising Competition: Report</a>
&#8220;Thus far in 2025, Workhorse has received purchase orders for a total of 27 W56 step vans, in both 178- and 208-inch wheelbases, as well as six W4 CC/W750 trucks,&#8221; said Workhorse CEO Rick Dauch.
&#8220;We are also currently negotiating with several potential customers regarding the purchase of additional W56 trucks,&#8221; the CEO added.
The company&#8217;s gross loss in the quarter under review narrowed to $4.523 million, compared with loss of $6.103 million a year ago.
As of March 31, the company had $2.6 million of cash and cash equivalents and $27.9 million in restricted cash net.
Workhorse <a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_ad867729314fa3424217b547b9a3dfed/workhorse/db/591/5720/presentation/WKHS+Q1+2025+Earnings+Presentation+5-14-25.pdf" rel="noreferrer noopener">said </a>it is working to save cash and extend its financial runway. It plans to sell more trucks in the second quarter of 2025 than it did in all of 2024.
The company aims to cut its monthly cash burn to $2.8 million by end-2024. Cost cuts include major workforce reductions and other savings steps.
Price Action: At last check Thursday, the company&#8217;s share price was down 7.36% at 92 cents. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020" target="_blank" rel="noreferrer noopener">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a></li>
</ul>

Earnings

Equities

Markets

General

WKHS

Workhorse Stock Slides After Q1 Miss, Plans To Cut Workforce To Curb Cash Burn

Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) with a Overweight and lowers the price target from $8 to $7.

Cantor Fitzgerald Maintains Overweight on Exagen, Lowers Price Target to $7

Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is riding its strongest rally in two years &#8211; and now, it's firing on all cylinders with a fresh catalyst: a <a href="https://www.benzinga.com//node/45410939">$6 billion stock buyback plan</a>. 
The announcement, coupled with a string of recent wins, has sent AMD shares soaring over 21% in the past month.
<h2 class="wp-block-heading">AMD Stock Technical Breakout In Progress</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png" alt="" class="wp-image-916673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
AMD has broken past resistance at around $115 and is charging toward its 200-day simple moving average (SMA) of $127.18. With the stock trading above its five, 20, and 50-day exponential moving averages, technical signals remain bullish. 
The MACD (moving average convergence/divergence) indicator at 4.4 suggests continued buying strength, though the RSI (relative strength index) sitting at the cusp of overbought conditions at 70, flags near-term caution.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png" alt="" class="wp-image-916675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Shorter-term indicators still support the momentum. The eight-day SMA at $107.24, the 20-day at $99.23, and the 50-day at $99.21 all sit well below the current price &#8211; reinforcing the trend strength. 
However, the stock has not yet cleared the 200-day SMA, which could act as a crucial test in coming sessions.
Read Also: <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a>
<h2 class="wp-block-heading">Buybacks, Big Deals, And Beating Expectations</h2>
The buyback boost brings AMD's total repurchase firepower to $10 billion, thanks to the existing $4 billion balance from a prior authorization. With $7.31 billion in cash on hand, AMD has room to keep rewarding shareholders.
Momentum has been building fast: the company recently posted first quarter earnings that beat expectations &#8211; $7.44 billion in revenue and 96 cents in adjusted EPS, topping estimates of $7.13 billion and 94 cents, respectively. It also announced a $10 billion data center deal in Saudi Arabia and inked a GPU cluster partnership with TensorWave.
From technical breakout to buyback buzz, AMD's rally has legs &#8211; and the bulls don't seem ready to let go just yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45437643/nvidia-now-worth-35x-intel-after-16-year-surge-and-valuation-gap-keeps-growing">Nvidia Now Worth 35x Intel After 16-Year Surge And Valuation Gap Keeps Growing</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Best AMD Stock Rally In 2 Years Gets A Buyback Boost

Rosenblatt analyst Blair Abernethy maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Buy and maintains $67 price target.

Rosenblatt Maintains Buy on Dynatrace, Maintains $67 Price Target

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy and maintains $33 price target.

ADVM

Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target

<a href="https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa</a>

'New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel'- WSJ

Cantor Fitzgerald analyst Deepak Mathivanan reiterates Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and maintains $170 price target.

EXPE

Cantor Fitzgerald Reiterates Neutral on Expedia Group, Maintains $170 Price Target

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock is trading lower on Thursday in reaction to a media report on a possible investigation for <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45426769/unitedhealth-stock-plunges-over-8-in-after-hours-trading-as-doj-criminal-probe-adds-to-turmoil-after-ceo-shake-up" rel="noreferrer noopener">criminal Medicare fraud</a>.
The Wall Street Journal <a href="https://www.wsj.com/us-news/unitedhealth-medicare-fraud-investigation-df80667f?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo">reported</a>, citing people familiar with the matter, that the healthcare-fraud unit of the Justice Department&#8217;s criminal division is overseeing the investigation, which has been active since at least last summer. 
UnitedHealth&#8217;s latest annual securities filing says the company &#8220;has been involved or is currently involved in various governmental investigations, audits and reviews,&#8221; and flags involved agencies including the Justice Department. 
It doesn&#8217;t specifically mention the criminal, civil and antitrust probes on which the Journal has reported.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44821140/unitedhealth-demands-rapid-repayment-of-cyberattack-relief-loan-billions-providers-say-push-undermines-recovery" rel="noreferrer noopener">UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery</a>
In a statement on Wednesday, the company <a target="_blank" href="https://www.unitedhealthgroup.com/newsroom/2025/2025-05-14-response-may-14-wsj-article.html" rel="noreferrer noopener">said</a>, &#8220;We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the&nbsp;Wall Street Journal today.&#8221;
&#8220;We stand by the integrity of our Medicare Advantage program,&#8221; the company statement continued.
On Tuesday, UnitedHealth CEO Andrew Witty abruptly announced his resignation and suspended its <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" target="_blank" rel="noreferrer noopener">fiscal year 2025 guidance</a>.
The insurance giant has garnered immense attention following the murder of its insurance unit CEO,&nbsp;Brian Thompson, in New York.
Luigi Mangione, the alleged perpetrator, pleaded not guilty to murder and weapons charges. Police found shell casings at the scene with the words &#8220;deny,&#8221; &#8220;defend,&#8221; and &#8220;depose,&#8221; commonly associated with insurance industry strategies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42771908/viral-tear-it-all-down-post-sparks-debate-over-unitedhealthcare-practices-alleges-denial-of-icu-care-for-comatose-patient" rel="noreferrer noopener">handling claims and disputes</a>.
According to a media report in February, the Justice Department reportedly launched a civil fraud investigation into&nbsp;UnitedHealth&#8217;s <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">Medicare billing practices</a>.
The WSJ&nbsp;<a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-medicare-doj-diagnosis-investigation-66b9f1db?mod=latest_headlines&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a>&nbsp;that Medicare paid substantial sums to UnitedHealth based on diagnoses added to patients&#8217; records, some of which doctors said were irrelevant or undocumented.
In March, a Special Master recommended granting&nbsp;UnitedHealth&#8217;s&nbsp;motion for summary judgment in a False Claims Act (FCA) case, concluding that the government lacks evidence&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44141489/false-claims-act-case-against-unitedhealth-faces-dismissal-recommendation" rel="noreferrer noopener">to support its allegations</a>.
In April, UnitedHealth got some relief when the Federal Trade Commission (FTC) paused the formal complaint against three major pharmacy benefit managers (PBMs) for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">price of insulin medications</a>.
Analyst Reaction:
<ul class="wp-block-list">
<li>Keybanc maintains UnitedHealth with an Overweight rating, lowering the <a href="https://www.benzinga.com/quote/UNH/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $575 to $450</a>.</li>
<li>Baird maintains UnitedHealth with an Outperform rating, lowering the price target from $510 to $356.</li>
<li>BofA Securities downgrades UnitedHealth from Buy to Neutral and lowers the price target from $560 to $350.</li>
<li>Morgan Stanley maintains UnitedHealth with an Overweight rating, lowering the price target from $563 to $374.</li>
<li>Wells Fargo maintains UnitedHealth with an Overweight, lowering the price target from $677 to $351.</li>
<li>Oppenheimer maintains UnitedHealth with an Outperform rating, lowering the price target from $600 to $400.</li>
<li>Deutsche Bank maintains UnitedHealth with a Buy, lowering the price target from $521 to $362.</li>
<li>JP Morgan maintains UnitedHealth with an Overweight, lowering the price target from $525 to $405.</li>
</ul>
Price Action: UnitedHealth stock is down 7.83% at $283.88 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45435748/dicks-sporting-goods-to-acquire-foot-locker-at-66-premium" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Goods To Acquire Foot Locker At 66% Premium</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Legal

Why Is UnitedHealth Stock Trading Lower On Thursday?

Press Releases

Bilibili Inc. Announces Third Quarter 2024 Financial Results

Bilibili Inc. Announces Completion of the Repurchase Right Offer for Its 0.50% Convertible Senior Notes due 2026

Entertainment

Indie Wuxia Sandbox RPG, The Matchless Kungfu, Slashes Prices by 25% in Steam Winter Sale, Now with German and Russian Localization

Bilibili Inc. to Report Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on Thursday, February 20, 2025

Bilibili Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Bilibili Inc. Files Its 2024 Annual Report on Form 20-F

Bilibili Publishes 2024 Environmental, Social and Governance Report

Bilibili Inc. to Hold Annual General Meeting on June 20, 2025

Bilibili Inc. to Report First Quarter 2025 Financial Results on Tuesday, May 20, 2025

Bilibili Inc. Announces Repurchase Right Notification for 1.25% Convertible Senior Notes due 2027

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Autohome

Baidu, Inc. - American Depositary Shares, each representing 8 ordinary share

Baidu

KANZHUN LIMITED - American Depository Shares

Kanzhun

CarGurus

Trump Media & Technology Group Corp. - Common Stock

Trump Media & Tech Gr

Trump Media & Technology Group Corp. - Warrants

Alphabet

Grindr

ZoomInfo Technologies Inc. - Common Stock

ZoomInfo Technologies

JOYY

Match Group

Pinterest

Reddit

Rumble

Snap

Taboola.com

Tripadvisor

Vtex

Weibo Corporation - American Depositary Shares

Weibo

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Comments

Bilibili

Noticias

Últimas noticias sobre Bilibili (NASDAQ:BILI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL